Medicare announces plan to negotiate prices of diabetes, weight loss drugs 15 drugs for conditions like cancer included in second round of price talks

Medicare announces plan to negotiate prices of diabetes, weight loss drugs 15 drugs for conditions like cancer included in second round of price talks https://www.statnews.com/2025/01/17/medicare-drug-price-negotiation-list-includes-ozempic-wegovy-ibrance-trelegy-ellipta-xtandi/?utm_campaign=morning_rounds&utm_medium=email&_hsenc=p2ANqtz-_oCfZr_ObXHLH1nrQpLf006j8AyjWI0RS3m-Qg0XrBfmtneXWdqMBheIYX7MI8JBgQAdUpApVfPoDFKievBhl1WcENyA&_hsmi=343359550&utm_content=343359550&utm_source=hs_email We knew this day was coming. The big news in drug pricing landed Friday, with diabetes and weight loss drugs Ozempic and Wegovy leading the list of 15 medications whose prices will be negotiated this year under the Inflation Reduction Act, a signature achievement for the Biden administration. That doesn’t mean it’s a done deal under the new president. Congress or Mehmet Oz, nominated to lead Medicare and Medicaid, could tinker with the program, which also includes drugs for cancer. STAT’s Rachel Cohrs Zhang has the story and Joe Grogan has his take in this First Opinion. Former Trump health official: Medicare should cover Wegovy — but not negotiate its price Price controls are a surefire way to crush innovation https://www.statnews.com/2025/01/17/former-trump-health-official-medicare-should-cover-wegovy-but-not-negotiate-its-price/?utm_campaign=morning_rounds&utm_medium=email&_hsenc=p2ANqtz-9jgUAChvWGhcGtqwJKWDvMv42Q6cPlBBuk3cIat38CqKWyrgxY3hGv5vJq1PmqnFL-2TERlStMd7XbMGVaoJ6QNcWBlA&_hsmi=343359550&utm_content=343359550&utm_source=hs_email

Online marketing for compounded GLP-1 drugs overstates benefits and underplays risks Dozens of sites mislead patients by suggesting compounded obesity drugs were approved by the FDA

https://www.statnews.com/2025/01/17/glp-1-drugs-compounded-weight-loss-drug-websites-fall-short-new-analysis/?utm_campaign=morning_rounds&utm_medium=email&_hsenc=p2ANqtz-9NkFEY6LEQaEAcSFjANGPbEWKiMl2B59NtuCLumx8OD6iNWrh80zPB9LkKj0G9SMFxV1hdwXGAcUC26EGNxoIhxuQnOQ&_hsmi=343359550&utm_content=343359550&utm_source=hs_email It’s hard to blame patients for being confused. When they pay cash for compounded versions of obesity drugs, they may assume they’re getting the same thing as brand-name Ozempic or Wegovy, FDA-approved and all, for a fraction of the price. But a new JAMA Health Forum study reveals that among 79 websites marketing compounded GLP-1s or prescriptions for them, 37% stated or implied that the drugs were FDA-approved. That’s not so. Nearly half didn’t include information about the drugs’ adverse effects, warnings, and contraindications and 41% of sites included unsupported efficacy claims. STAT’s Katie Palmer has more on this gray area of regulation. Online Advertising of Compounded Glucagon-Like Peptide-1 Receptor Agonists https://jamanetwork.com/journals/jama-health-forum/fullarticle/2829225?utm_term=011725&utm_campaign=ftm_links&utm_medium=referral&_hsenc=p2ANqtz-9Md0RD_z3-0BFYIU_bDyeJgbxJbdCCo7dQNGCW2ChfOHtLwq3zgxBQ0AadZ7FsGhdzZa9BLWaghGwSipcOsQ8Y28GqhQ&_hsmi=343359550&utm_source=For_The_Media

As targeted therapies prevail, patient voice and preference should, too

https://www.statnews.com/sponsor/2025/01/06/as-targeted-therapies-prevail-patient-voice-and-preference-should-too/

Childhood Thyroid Cancer Treatment (PDQ®)–Health Professional Version

https://www.cancer.gov/types/thyroid/hp/child-thyroid-treatment-pdq?cid=eb_govdel#top

Childhood Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version

https://www.cancer.gov/types/leukemia/hp/child-aml-treatment-pdq?cid=eb_govdel#top

Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version

https://www.cancer.gov/types/lymphoma/hp/adult-hodgkin-treatment-pdq?cid=eb_govdel#top Hodgkin Lymphoma Treatment During Pregnancy (PDQ®)–Health Professional Version https://www.cancer.gov/types/lymphoma/hp/hodgkin-lymphoma-treatment-during-pregnancy-pdq?cid=eb_govdel#top

Contraceptive Prescribing Among People Treated for Opioid Use Disorder

https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2829199?guestAccessKey=a919cfbf-f217-4b5b-9974-5ea264ae8202&utm_term=012125&utm_campaign=ftm_links&utm_medium=referral&_hsenc=p2ANqtz-_cBOfejRiv1seM6PF0cAmrfDKKMwO4TC_IMn2rbQ076MQRm8PaZicT8wtDGdltEk1nrnwv8lvdj_yhivtg63kmvKI3hQ&_hsmi=343569311&utm_content=tfl&utm_source=For_The_Media Women with opioid use disorder aren’t getting as much birth control Women being treated for opioid use disorder are less likely to be prescribed birth control than those in the general population, according to a study published yesterday in JAMA Internal Medicine. Researchers analyzed commercial insurance claims data from cisgender women ages 18 to 44 between 2016 and 2021. While contraceptive prescriptions increased among women in the U.S. generally over the time period, from about 17% to 27%, the prescriptions decreased among those prescribed medications for opioid use disorder, from just over 12% in 2016 to 11.6% in 2021. It’s a sign that people struggling with addiction are not getting integrated, patient-centered birth control counseling as recommended by professional organizations, the authors write.